近日，广州一支科研团队在肝癌介入治疗领域取得重要突破，发现了一种调控肿瘤微环境的关键分子机制，为提升肝癌介入治疗效果提供了新思路。该研究由中山大学附属第一医院联合华南理工大学等机构共同完成，相关成果已发表于国际权威期刊《自然·通讯》。研究团队发现，在经导管动脉化疗栓塞术（TACE）等介入治疗过程中，肿瘤组织中一种名为‘CXCL12’的趋化因子显著上调，会招募免疫抑制性细胞进入肿瘤微环境，从而削弱治疗效果并促进肿瘤复发。通过靶向阻断CXCL12信号通路，研究人员在动物模型中显著增强了TACE的抗肿瘤作用，并延长了生存期。这一发现不仅揭示了肝癌对介入治疗产生抵抗的新机制，也为开发联合免疫治疗策略提供了理论依据。未来，该团队计划开展临床试验，验证CXCL12抑制剂与TACE联用的安全性和有效性，有望为中晚期肝癌患者带来更优治疗方案。
Recently, a research team from Guangzhou has made a significant breakthrough in interventional therapy for liver cancer by uncovering a key molecular mechanism that regulates the tumor microenvironment, offering new insights to enhance treatment efficacy. Conducted jointly by the First Affiliated Hospital of Sun Yat-sen University and South China University of Technology, the study was published in the prestigious international journal Nature Communications. The researchers discovered that during interventional procedures such as Transarterial Chemoembolization (TACE), the chemokine CXCL12 is markedly upregulated in tumor tissues. This increase recruits immunosuppressive cells into the tumor microenvironment, thereby diminishing therapeutic effectiveness and promoting tumor recurrence. In animal models, targeted blockade of the CXCL12 signaling pathway significantly enhanced the anti-tumor effects of TACE and prolonged survival. This finding not only reveals a novel mechanism underlying liver cancer’s resistance to interventional therapy but also provides a theoretical foundation for developing combination immunotherapies. The team now plans to initiate clinical trials to evaluate the safety and efficacy of combining CXCL12 inhibitors with TACE, potentially offering improved treatment options for patients with intermediate to advanced-stage liver cancer.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/16557.html